A pilot study to evaluate the efficacy and safety of prophylactic Romiplostim in preventing Grade 4 thrombocytopenia in multiple myeloma and lymphoma patients undergoing Autologous stem cell transplant
Main Article Content
Abstract
Background and Introduction: During Autologous stem cell transplant, one of the dreaded complications is Grade 4 thrombocytopenia, which leads to prolonged hospitalization and increased transfusion requirement. This pilot study aims to evaluate the efficacy and safety of prophylactic romiplostim in preventing grade 4 thrombocytopenia in this patient population.
Methods: From January 2024 to march 2025, an open label pilot study was conducted with 26 eligible adult patients undergoing Autologous stem cell transplant in a tertiary care oncology center. Beginning from day +1 post-transplant Romiplostim (250 mcg SC) was administered weekly until platelet engraftment. Results were compared with historical controls who did not receive romiplostim. Complete blood counts, transfusion requirements, adverse events and engraftment timelines were assessed on daily basis and documented. Statistical analysis was performed using appropriate comparative methods; p<0.05 was considered significant.
Results: Use of romiplostim reduced the incidence of grade 4 thrombocytopenia in multiple myeloma patients who received melphalan- 200mg/m2 as conditioning regimen (27.3% reduction, p=0.04). Also, there was a significant reduction in single donor platelet transfusion requirement in this group(p=0.03). Platelet engraftment was faster across all conditioning regimens in the intervention group. Neutrophil engraftment and duration of hospital stay were comparable. There were no major bleeding or thrombotic adverse events reported. An exploratory cost benefit analysis showed potential economic advantages due to decreased transfusion requirements.
Conclusion: Prophylactic romiplostim administration during Autologous stem cell transplant is a safe, effective intervention in reducing grade 4 thrombocytopenia and platelet transfusion requirements. Larger studies are warranted to confirm these findings.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23.
3. Cheng G, Saleh MN, Marcher C, et al. Long-term safety of romiplostim in adult patients with chronic immune thrombocytopenia. Br J Haematol. 2020;189(5):934–944.
4. Prakash V, Aboulafia DM. Romiplostim for persistent thrombocytopenia post-transplant: a review. J Blood Med. 2016;7:99–106.
5. Obara N, Fujisawa S, Okamoto S, et al. Long-term real-world safety and effectiveness of romiplostim in Japanese patients with ITP. Int J Hematol. 2024;120(6):665–674.
6. Wu Y, Aravind S, Raghavan D, et al. Incidence of dose delays, reductions, and relative dose intensity in chemotherapy-induced thrombocytopenia. J Natl Compr Canc Netw. 2015;13(11):1383–1392.
7. Desai P, Srivastava S, Gupta N, et al. Thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: a narrative review. J Hematol Oncol. 2022;15(1):30.
8. Soff GA, Carney DH, Bonavida B, et al. Romiplostim for the management of chemotherapy-induced thrombocytopenia: a phase II randomized trial. J Clin Oncol. 2019;37(31):2892–2898.
9. Liu Y, Jin Y, Liu T, et al. Efficacy and safety of thrombopoietin receptor agonists for thrombocytopenia after hematopoietic stem cell transplantation: a systematic review and meta-analysis. Front Pharmacol. 2022;13:872391.
10. Scordo M, Gilbert LJ, Hanley DM, et al. Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation. Blood Adv. 2023;7(8):1536–1544.
11. Vadlamani SP, Nair RR, Soneji D, et al. Romiplostim reduces platelet transfusion needs in multiple myeloma patients undergoing autologous stem cell transplantation. Cureus. 2024;16(12):e76164.
12. Grainger J, Bosanquet A, Moore J, et al. Use of thrombopoietin mimetics to manage cytopenias following hematopoietic cell transplantation. Bone Marrow Transplant. 2022;57(7):1111–1118.
13. Huang J, Li X, Wang X, et al. Thrombopoietin receptor agonists in hematopoietic stem cell transplantation: a systematic review. Transfusion. 2021;61(2):480–492.
14. Christakopoulos GE, Shastri A, Levine JE, et al. A phase I study of romiplostim after umbilical cord blood transplantation. Transplant Cell Ther. 2021;27(1):86.e1–86.e7.
15. Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of romiplostim in patients with chronic ITP: final results of a phase 3 trial. Lancet. 2014;384(9950):729–737.
16. Kimura S, Saitoh T, Ohsaka A, et al. Romiplostim in patients with thrombocytopenia after chemotherapy. Am J Hematol. 2017;92(12):1211–1217.
17. Buchbinder D, Nugent DJ, Freedman J, et al. Romiplostim use in pediatric patients with chronic ITP: a real-world study. Drug Des Devel Ther. 2017;11:1055–1063.
18. Roy S. Thrombopoietin receptor agonists as potential treatment for thrombocytopenia in dengue and other viral infections. Cureus. 2019;11(4):e4361.
19. Zhou H, Sun W, Li Y, et al. Romiplostim in persistent/chronic ITP: a phase III randomized trial in China. Res Pract Thromb Haemost. 2023;7(4):e100520.
20. Lee D, Duffy S, Doucette S. Cost-effectiveness of romiplostim for the treatment of chronic ITP in Ireland. Appl Health Econ Health Policy. 2013;11(5):457–469.
21. Cheng J, Zhang L, Sun Z, et al. Cost-effectiveness of thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia in China. BMC Cancer. 2022;22(1):135.
22. Lambert J, Lugthart S, Vellenga E, et al. Clinical impact of thrombocytopenia after autologous stem cell transplantation in myeloma. Bone Marrow Transplant. 2020;55:1561–1569.
23. Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the role of TPO mimetics. Blood. 2014;124(18):2775–2783.
24. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncologist. 2015;20(6):598–609.
25. Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–1123.
26. Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735.
27. Manko J, et al. Cost-effectiveness of romiplostim for immune thrombocytopenia: a systematic review. Eur J Haematol. 2021;107(4):379–388.
28. Patel V, et al. Outcomes of thrombopoietin receptor agonists in stem cell transplant-associated thrombocytopenia: a multicenter review. Leuk Lymphoma. 2022;63(9):2054–2062.
29. NCCN. Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 2.2024.